Nippon India Pharma Fund - IDCW - Direct Plan

Other Plans and Options
  • 1.9 %Nav, as on 13-08-2025

  • Previous Nav

  • Net Change on 13-08-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option -1.31 4.81 2.91 23.30 19.29 17.93
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A
BSE SENSEX - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option Jan 01, 2013 2.91 23.30 19.29 0.89 8,736.57
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - IDCW Option Jul 13, 2018 9.45 28.39 22.07 1.04 6,103.96
SBI Healthcare Opportunities Fund - Direct Plan - Income Distribution cum Capital Withdrawal Option (IDCW) Jan 01, 2013 11.51 27.64 21.28 0.91 4,026.55
Mirae Asset Healthcare Fund Direct IDCW Jul 02, 2018 5.29 22.67 20.15 0.48 2,908.21
TATA India Pharma & Health Care Fund Direct Plan - Payout of Income Distribution cum capital withdrawal option Dec 28, 2015 4.88 24.98 20.33 0.61 1,339
TATA India Pharma & Healthcare Fund Direct Plan - Reinvestment of Income Distribution cum capital withdrawal option Dec 28, 2015 4.88 24.98 20.33 0.61 1,339

Fund Holdings as on 31-July-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Lupin Limited

  • Cipla Limited

  • Dr. Reddy's Laboratories Limited

  • Apollo Hospitals Enterprise Limited

  • MedPlus Health Services Limited

  • Vijaya Diagnostic Centre Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Gland Pharma Limited

  • Ajanta Pharma Limited

  • Abbott India Limited

  • Thyrocare Technologies Limited

  • Dr. Lal Path Labs Limited

  • Sai Life Sciences Limited

  • Narayana Hrudayalaya Limited

  • Mankind Pharma Limited

  • Aurobindo Pharma Limited

  • Zydus Lifesciences Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Pfizer Limited

  • Alkem Laboratories Limited

  • Biocon Limited

  • Sanofi India Limited

  • Suraksha Diagnostic Limited

  • IPCA Laboratories Limited

  • Torrent Pharmaceuticals Limited

  • Sanofi Consumer Healthcare India Limited

  • Fortis Healthcare Limited

  • Syngene International Limited

  • Anthem Biosciences Limited

  • Akums Drugs and Pharmaceuticals Limited

  • Emcure Pharmaceuticals Limited

  • Indoco Remedies Limited

  • AstraZeneca Pharma India Limited

  • Orchid Pharma Limited

  • Net Current Assets

  • Triparty Repo

  • Concord Biotech Limited

  • Cash Margin - CCIL

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Business Support

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 21/02/2025

  • 26/02/2024

  • 28/02/2022

  • 01/03/2021

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹8,736.57 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended up ₹3.18(1.9%)yesterday to ₹170.5489.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097